<DOC>
	<DOCNO>NCT01709838</DOCNO>
	<brief_summary>To assess efficacy deferasirox patient non-transfusion dependent thalassemia base change liver iron concentration baseline 52 week treatment . To provide assessment long-term efficacy safety deferasirox NTDT patient iron overload ( LIC ≥ 5 mg Fe/g liver dw SF ≥ 300 ng/mL ) 260 week .</brief_summary>
	<brief_title>Efficacy Safety Study Deferasirox Patients With Non-transfusion Dependent Thalassemia</brief_title>
	<detailed_description>To assess efficacy deferasirox patient non-transfusion dependent thalassemia base change liver iron concentration baseline 52 week . Also , evaluate impact deferasirox quality life adult pediatric patient ; correlate change serum ferritin LIC , evaluate efficacy change NTDT syndrome , evaluate high dos deferasirox , assess endocrine function examine PK parameters.To also assess efficacy treatment patient high LIC ( &gt; 15 mg Fe/g dw ) baseline need re-treatment reach target LIC &lt; 3 mg Fe/g dw study .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Nontransfusion dependent congenital chronic anemia inclusive betathalassemia intermedia , HbE betathalassemia alphathalassemia intermedia ( HbH disease ) / Liver iron concentration &gt; /= 5 mg Fe/g dw Serum Ferritin &gt; /= 300 ng/mL HbSbeta Thalassemia , anticipate regular transfusion program study , blood transfusion 6 month prior study start , significant proteinuria , creatinine clearance &lt; /= 40 ml/min , serum creatinine &gt; ULN , ALT &gt; 5 x ULN , active hepatitis B C , cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Non-transfusion dependent thalassemia , NTDT</keyword>
</DOC>